Everest Group Names Medidata a ‘Leader’ and ‘Star Performer’ in Decentralized Clinical Trial Platforms
13 Dec 2022
Clinical Study
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes company, has been named a Leader and Star Performer in the “Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023” by Everest Group. The annual report evaluates decentralized clinical trial (DCT) products from 24 companies based on vision, capability, and market impact.
“Medidata provides a modular DCT platform with a unified data layer. Its solution is highly recognized for governance, security, and compliance by clients,” said Chunky Satija, vice president at Everest Group. “Medidata’s investments towards standardizing the site operations, improving the ease of use of the platform, expanding access to clinical trials, and unifying reporting from a single data platform have put Medidata into a leader’s position in the decentralized clinical trial platforms PEAK Matrix Assessment.”
Leaders in the DCT Platforms PEAK Matrix Assessment:
Offer clients an end-to-end modular platform with a unified data model that allows all patient data to be in a single repository, eliminating data silos
Provide the auxiliary services required to run a DCT
Are ranked high on user and patient experience, and they offer advanced use cases to clients (such as advanced analytics and patient recruitment campaigns) to enable them to run their DCTs
Work proactively toward building market awareness and stakeholder education via various forums and enjoy high mindshare and brand perception
“As the industry has evolved and demand for DCTs has grown, Medidata has been at the forefront of driving innovation for patient-centric technologies,” said Anthony Costello, CEO of Medidata Patient Cloud. “Recognition from Everest as both a Leader and Star Performer validates the success we have gained with our sponsors and CROs. Our depth and breadth of solutions across therapy areas, and our project management capabilities were key to earning our spot as a Leader.”
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.